Your browser doesn't support javascript.
loading
De novo and biallelic DEAF1 variants cause a phenotypic spectrum.
Nabais Sá, Maria J; Jensik, Philip J; McGee, Stacey R; Parker, Michael J; Lahiri, Nayana; McNeil, Evan P; Kroes, Hester Y; Hagerman, Randi J; Harrison, Rachel E; Montgomery, Tara; Splitt, Miranda; Palmer, Elizabeth E; Sachdev, Rani K; Mefford, Heather C; Scott, Abbey A; Martinez-Agosto, Julian A; Lorenz, Rüdiger; Orenstein, Naama; Berg, Jonathan N; Amiel, Jeanne; Heron, Delphine; Keren, Boris; Cobben, Jan-Maarten; Menke, Leonie A; Marco, Elysa J; Graham, John M; Pierson, Tyler Mark; Karimiani, Ehsan Ghayoor; Maroofian, Reza; Manzini, M Chiara; Cauley, Edmund S; Colombo, Roberto; Odent, Sylvie; Dubourg, Christele; Phornphutkul, Chanika; de Brouwer, Arjan P M; de Vries, Bert B A; Vulto-vanSilfhout, Anneke T.
Afiliação
  • Nabais Sá MJ; Department of Human Genetics, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Jensik PJ; Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.
  • McGee SR; Department of Physiology, Southern Illinois University School of Medicine, Carbondale, IL, USA.
  • Parker MJ; Sheffield Clinical Genetics Service, OPD2 Northern General Hospital, Sheffield, UK.
  • Lahiri N; Department of Clinical Genetics, St George's University Hospitals NHS Foundation Trust & St George's, University of London, London, UK.
  • McNeil EP; Dartmouth Geisel School of Medicine, Hanover, NH, USA.
  • Kroes HY; Department of Genetics, University Medical Center Utrecht, Utrecht, The Netherlands.
  • Hagerman RJ; Medical Investigation of Neurodevelopmental Disorders (MIND) Institute, University of California Davis School of Medicine, Sacramento, Sacramento, CA, USA.
  • Harrison RE; Department of Pediatrics, University of California Davis Medical Center, Sacramento, Sacramento, CA, USA.
  • Montgomery T; Department of Clinical Genetics, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Splitt M; Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Palmer EE; Northern Genetics Service, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.
  • Sachdev RK; Sydney Children's Hospital, Randwick, NSW, Australia.
  • Mefford HC; School of Women's and Children's Health, UNSW Medicine, The University of New South Wales, Sydney, NSW, Australia.
  • Scott AA; Sydney Children's Hospital, Randwick, NSW, Australia.
  • Martinez-Agosto JA; School of Women's and Children's Health, UNSW Medicine, The University of New South Wales, Sydney, NSW, Australia.
  • Lorenz R; Department of Pediatrics, Division of Genetic Medicine, University of Washington-Seattle, Seattle, WA, USA.
  • Orenstein N; Division of Genetic Medicine, Seattle Children's Hospital, Seattle, WA, USA.
  • Berg JN; Department of Human Genetics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Amiel J; Division of Medical Genetics, Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • Heron D; Ludwig-Konrad-Str. 14, Bad Wildungen, Germany.
  • Keren B; Pediatric Genetics Clinic, Schneider Children's Medical Center of Israel, Petach Tikva, Israel.
  • Cobben JM; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Menke LA; Department of Clinical Genetics, Ninewells Hospital and Medical School, Dundee, Angus, UK.
  • Marco EJ; Clinical Genetics, University of Dundee, Dundee, Angus, UK.
  • Graham JM; Département de Génétique, Hôpital Necker-Enfants Malades, Assistance Publique, INSERM UMR 1163, Institut Imagine, Paris, France.
  • Pierson TM; Département de Génétique, Hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Paris, France.
  • Karimiani EG; Département de Génétique, Hôpital Pitié-Salpêtrière, Assistance publique-Hôpitaux de Paris, Paris, France.
  • Maroofian R; Department of Pediatrics, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Manzini MC; North West Thames Genetics NHS, Northwick Park Hospital, London, UK.
  • Cauley ES; Department of Pediatrics, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
  • Colombo R; Department of Child Neurology, Cortica Healthcare, San Rafael, CA, USA.
  • Odent S; Division of Clinical Genetics and Dysmorphology, Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Dubourg C; Department of Pediatrics, Department of Neurology, and the Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
  • Phornphutkul C; Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London, London, UK.
  • de Brouwer APM; Genetics Research Centre, Molecular and Clinical Sciences Institute, St George's, University of London, London, UK.
  • de Vries BBA; GW Institute for Neuroscience, Department of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
  • Vulto-vanSilfhout AT; GW Institute for Neuroscience, Department of Pharmacology and Physiology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
Genet Med ; 21(9): 2059-2069, 2019 09.
Article em En | MEDLINE | ID: mdl-30923367
ABSTRACT

PURPOSE:

To investigate the effect of different DEAF1 variants on the phenotype of patients with autosomal dominant and recessive inheritance patterns and on DEAF1 activity in vitro.

METHODS:

We assembled a cohort of 23 patients with de novo and biallelic DEAF1 variants, described the genotype-phenotype correlation, and investigated the differential effect of de novo and recessive variants on transcription assays using DEAF1 and Eif4g3 promoter luciferase constructs.

RESULTS:

The proportion of the most prevalent phenotypic features, including intellectual disability, speech delay, motor delay, autism, sleep disturbances, and a high pain threshold, were not significantly different in patients with biallelic and pathogenic de novo DEAF1 variants. However, microcephaly was exclusively observed in patients with recessive variants (p < 0.0001).

CONCLUSION:

We propose that different variants in the DEAF1 gene result in a phenotypic spectrum centered around neurodevelopmental delay. While a pathogenic de novo dominant variant would also incapacitate the product of the wild-type allele and result in a dominant-negative effect, a combination of two recessive variants would result in a partial loss of function. Because the clinical picture can be nonspecific, detailed phenotype information, segregation, and functional analysis are fundamental to determine the pathogenicity of novel variants and to improve the care of these patients.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Deficiências do Desenvolvimento / Proteínas de Ligação a DNA / Deficiência Intelectual / Microcefalia Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Deficiências do Desenvolvimento / Proteínas de Ligação a DNA / Deficiência Intelectual / Microcefalia Tipo de estudo: Prognostic_studies Limite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Male Idioma: En Revista: Genet Med Assunto da revista: GENETICA MEDICA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Holanda